Peptide questions · Petrelintide
How long does petrelintide take to work?
Reviewed Evidence: ModeratePublished by PepVault
Petrelintide’s onset is days–2 weeks, its peak effect comes at 42 weeks (phase 2, still falling), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 1 (Brændholt Olsen 2026, Diabetes Obes Metab), ZUPREME-1 (Garvey 2026, Lancet Diabetes Endocrinol; NCT06662539), Zealand release Oct-7-2026 (ZUPREME-2), ZUPREME-3/4/5 records on ClinicalTrials.gov. Investigational.
Petrelintide week by week
The library places six of its research notes on petrelintide on the days they cover, from day 1 to day 294: 5 on randomized trials and 1 on clinical data.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–28 (weeks 1–4) | Fullness, gently | Randomized trial |
| Days 29–294 (weeks 5–42) | Low doses already work | Randomized trial |
| Days 57–294 (weeks 9–42) | Five milligrams | Randomized trial |
| Days 85–294 (weeks 13–42) | The top dose tested | Randomized trial |
| Days 85–294 (weeks 13–42) | With type 2 diabetes | Clinical data |
| Days 197–294 (weeks 29–42) | Weeks 28 to 42: still moving | Randomized trial |

Model. Individual results vary.
The petrelintide timeline’s milestones
The library’s timeline for petrelintide marks 5 points from week 1 to week 42, backed by moderate evidence overall.
- Week 1: Commonly reported: feeling full sooner at meals
- Week 4: Its phase 2 trials stepped the dose up every 4 weeks, for up to 16 weeks
- Week 16: Phase 1: up to about 8.6% loss after 16 weekly doses, without diet advice
- Week 28: ZUPREME-1 endpoint: about 8% to 10% average loss vs about 2% on placebo
- Week 42: ZUPREME-1 end: up to about 10.7% average loss, still coming down
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why petrelintide takes that long
Petrelintide’s half-life is about 10 days (240 hours), so one dose is about 96.9% cleared after 50 days.
On its schedule (Weekly) the doses overlap, and the level of petrelintide keeps climbing for about 40–50 days before it levels off, so the first 40–50 days run below the level the later weeks hold.
The notes on petrelintide follow the trials’ dose steps, 2.5mg, 5mg and 9mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Petrelintide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, petrelintide among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does petrelintide take to work?
Petrelintide’s onset is days–2 weeks, its peak effect comes at 42 weeks (phase 2, still falling), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does petrelintide reach its peak effect?
By the library’s timeline, petrelintide’s peak effect comes at 42 weeks (phase 2, still falling), backed by moderate evidence.
How long is petrelintide usually run?
The library’s timeline gives petrelintide’s typical duration as ongoing; its cycle note says: Used continuously, once weekly, in its trials: 42 weeks in ZUPREME-1 and 28 weeks in ZUPREME-2, with steps every 4 weeks.
What does the library say about the first days on petrelintide?
Its first note on petrelintide, for days 1–28 (weeks 1–4), is “Fullness, gently”, resting on randomized trials.